Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
PhaseBio Pharmaceuticals Inc (PHAS)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | S-1/A |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | | 100.0% |
| Cost of goods sold | 0.0% | 0.0% | 0.0% | 0.0% | | 128.8% |
| Gross profit | 100.0% | 100.0% | 100.0% | 100.0% | | -28.8% |
| Research and development | 942.7% | 22527.5% | 1309.2% | 2313.6% | | |
| General and administrative | 148.5% | 4090.0% | 473.8% | 727.1% | | 28.8% |
| EBITDA | -974.7% | -26358.8% | -1675.6% | -2925.0% | | -127.6% |
| Depreciation | 16.6% | 158.8% | 7.4% | 15.7% | | 1.2% |
| EBIT | -991.2% | -26517.5% | -1683.0% | -2940.7% | | -128.8% |
| Pre-tax income | -1195.4% | -30801.6% | -1662.3% | -3569.8% | | -125.0% |
| Income taxes | 14.8% | 0.0% | 0.0% | 0.0% | | 0.0% |
| Net income | -1210.1% | -30801.6% | -1662.3% | -3569.8% | | -125.0% |
|